Skip to main content
OpenTrials
Completed

NCT Number: NCT02452736

Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

The purpose of this study is to conduct a prospective, multi-center, single arm, non-randomized evaluation of acute outcomes in Chinese subjects, including those eligible for percutaneous transluminal coronary angioplasty (PTCA) with a reference vessel diameter of 2.25 mm to 4.0 mm, with the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Heart Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Wuhan Asia Heart Hospital, Wuhan, Hubei, China

Loading trial locations.

About this study

This is a Pre-market, Prospective, Multi-center, Single arm, Non-randomized Study.

The objective of this study is to:

  • To assess the deliverability of the Resolute Integrity Stent for suitable patients according to Indication for Use with a reference vessel diameter (RVD) of 2.25 mm to 4.0 mm in 200 evaluable patients
  • To assess the in-hospital Major Adverse Cardiac Event (MACE) rate
  • To collect data on resource utilization in the catheterization lab. At least 200 evaluable patients from about 15 study centers in China who meet the eligibility criteria and sign the informed consent form will participate in this study.

The expected time of participation in the study for each subject is from informed consent sign-off up to hospital discharge.

An angiographic core laboratory and a Clinical Events Committee (CEC) will be utilized. Adjudication of pre-specified clinical endpoint events will be done by an independent Clinical Events Committee. An angiographic core laboratory will review all baseline, procedural, and clinical event angiograms for all patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is older than or equal to 18 years
  • The patient is an acceptable candidate for treatment with a drug-eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, the Instructions for Use of the Resolute Integrity stent
  • The patient or legal representative has been informed of the nature of the trial and has consented to participate and authorized the collection and release of his/her medical information by signing a Patient Informed Consent Form
  • Intention to implant at least one Resolute Integrity stent during percutaneous coronary intervention (PCI)
  • Patient agrees to have all study procedures performed, and is willing to comply with all protocol-required evaluations

Exclusion criteria

  • Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin, clopidogrel and ticlopidine, cobalt, nickel, chromium, molybdenum, polymer coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequately pre-medicated
  • History of an allergic reaction or significant sensitivity to drugs such as zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative
  • A woman who is pregnant, planning to be pregnant or lactating
  • Currently participating in another trial
  • Situation that will prevent dual anti-platelet therapy to be maintained throughout the peri-surgical period
  • Previous enrollment in the China Resolute Integrity Study

Treatment and study plan

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System

Device

Primary outcomes

  1. Device Specific Procedural Success

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days.

    Defined as device success (the attainment of less than 50% residual stenosis of the target lesion using only the study device) and no in-hospital MACE (composite of death, myocardial infarction, emergent coronary bypass surgery, or clinically-driven repeat target lesion revascularization).

Secondary outcomes

  1. Delivery Success

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Defined as complete passage of the Resolute Integrity stent across the target lesion with full expansion of the stent to the desired diameter at the desired location.

  2. Device Success

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    defined as the attainment of less than 50% residual stenosis of the target lesion using only the Resolute Integrity stent.

  3. Lesion Success

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Defined as the attainment of less than 50% residual stenosis by any percutaneous method.

  4. Procedure Success

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days.

    Defined as the attainment of less than 50% residual stenosis by any percutaneous method and no in-hospital MACE.

  5. In-hospital Major Adverse Cardiac Events (MACE)

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days.

    Defined as the composite of as in-hospital death, myocardial infarction (Q-wave and non Q-wave), emergent coronary bypass surgery, or repeat target lesion revascularization (TLR; clinically driven/clinically indicated) by percutaneous or surgical method.

  6. In-hospital Target Lesion Failure (TLF)

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days.

    Defined as the composite of cardiac death, myocardial infarction (not clearly attributable to a non-target vessel) or target lesion revascularization (TLR; clinically indicated).

  7. Procedure time (min)

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Resource Utilization

  8. Contrast volume used (ml)

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Resource Utilization

  9. Usage of guiding catheters

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Resource Utilization

  10. Usage of guide wires

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Resource Utilization

  11. Usage of angioplasty balloons

    Time frame: Participants will be followed at the end of index procedure, an expected average of 3 days.

    Resource Utilization

Sponsors and collaborators

Lead sponsor

Medtronic Vascular

Industry

Registry information

Official study title

CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
May 25, 2015
Registry last updated
Apr 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.